These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 22420065

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Amendment of the fee exemption for federal, state and local government employees--DEA, Justice. Final rule.
    Fed Regist; 1994 Feb 24; 59(37):8859. PubMed ID: 10133414
    [Abstract] [Full Text] [Related]

  • 23. Exemption of chemical mixtures. Final rule.
    Drug Enforcement Administration (DEA), U.S. Department of Justice.
    Fed Regist; 2007 Mar 12; 72(47):10925-8. PubMed ID: 17450656
    [Abstract] [Full Text] [Related]

  • 24. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2005 Jun 23; 70(120):36338-44. PubMed ID: 15973789
    [Abstract] [Full Text] [Related]

  • 25. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2002 Oct 07; 67(194):62354-70. PubMed ID: 12369590
    [Abstract] [Full Text] [Related]

  • 26. Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2010 Jun 29; 75(124):37295-9. PubMed ID: 20608285
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Retail sales of scheduled listed chemical products; self-certification of regulated sellers of scheduled listed chemical products. Interim final rule with request for comment.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2006 Sep 26; 71(186):56008-27. PubMed ID: 17017470
    [Abstract] [Full Text] [Related]

  • 29. Import and production quotas for certain List I chemicals. Interim final rule with request for comment.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2007 Jul 10; 72(131):37439-53. PubMed ID: 17674492
    [Abstract] [Full Text] [Related]

  • 30. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2004 Mar 18; 69(53):12794-7. PubMed ID: 15029891
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Designation of oripavine as a basic class of controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2007 Sep 24; 72(184):54208-10. PubMed ID: 17912784
    [Abstract] [Full Text] [Related]

  • 33. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
    Fed Regist; 2000 Apr 24; 65(79):21645-7. PubMed ID: 11010670
    [Abstract] [Full Text] [Related]

  • 34. Dispensing of controlled substances to assist suicide. Interpretive rule.
    Department of Justice.
    Fed Regist; 2001 Nov 09; 66(218):56607-8. PubMed ID: 11760766
    [Abstract] [Full Text] [Related]

  • 35. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2013 May 16; 78(95):28735-9. PubMed ID: 23678676
    [Abstract] [Full Text] [Related]

  • 36. Clarification of registration requirements for individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2006 Dec 01; 71(231):69478-80. PubMed ID: 17171847
    [Abstract] [Full Text] [Related]

  • 37. Exempt chemical mixtures containing gamma-butyrolactone. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2010 Jun 29; 75(124):37301-7. PubMed ID: 20608286
    [Abstract] [Full Text] [Related]

  • 38. Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2003 Apr 04; 68(65):16427-30. PubMed ID: 12678045
    [Abstract] [Full Text] [Related]

  • 39. Definition of "positional isomer" as it pertains to the control of schedule I controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2007 Dec 03; 72(231):67850-2. PubMed ID: 18064769
    [Abstract] [Full Text] [Related]

  • 40. Changes to patient limitation for dispensing or prescribing approved narcotic controlled substances for maintenance or detoxification treatment by qualified individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2008 May 22; 73(100):29685-8. PubMed ID: 18605404
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.